An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension

Trial Profile

An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension

Recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Aug 2017

At a glance

  • Drugs Bardoxolone methyl (Primary)
  • Indications Pulmonary hypertension
  • Focus Adverse reactions; Expanded access
  • Acronyms RANGER
  • Sponsors Reata Pharmaceuticals
  • Most Recent Events

    • 19 Apr 2017 Status changed from not yet recruiting to recruiting.
    • 07 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top